Related Experiment Video
Updated: Jul 5, 2026
Yeast As a Chassis for Developing Functional Assays to Study Human P53
Published on: August 4, 2019
Clinical and Biological Implications of TP53 Abnormalities in Relapsed/Refractory Multiple Myeloma: The DEDALO Study
Vittorio Montefusco1, Anna Maria Cafro2, Gloria Margiotta-Casaluci3
1Hematology Department, ASST Santi Paolo e Carlo, Milano, Italy.
Background:
Pomalidomide-daratumumab-dexamethasone (DPd) has been shown to be effective in lenalidomide-exposed patients with multiple myeloma (MM). We aimed to evaluate this combination in patients with del(17p), for whom there is no specific treatment.
Patients And Methods:
The phase II DEDALO study enrolled patients with relapsed/refractory (RR)MM, del(17p), and ≤ 3 previous therapy lines including lenalidomide. Patients received DPd according to the approved schedule. The primary endpoint was minimal residual disease (MRD) negativity (by next-generation sequencing, 10-5 sensitivity).
Results:
Fifty patients were enrolled, and 45 were eligible. A del(17p) clone size ≥ 55% was observed in 26/45 patients, while TP53 mutations in 10/31. One patient achieved MRD negativity. With a median follow-up of 18.7 months, the median progression-free survival (PFS) was 7.0 months (4.3-13.9) overall, 6.5 in patients with a del(17p) clone size < 55%, 7.6 in those with a clone size ≥ 55%, 3.2 in those with biallelic TP53 alteration, and 11.8 in those with isolated del(17p). Toxicity was consistent with previous studies.
Conclusion:
This is the first study testing a specific treatment for MM patients with del(17p). We confirmed the severity of this abnormality, particularly in the presence of double TP53 inactivation, and the importance of a thorough biological characterization.
